Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. - Wikidata - wikimedia - TriplyDB

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

http://www.wikidata.org/entity/Q33708774

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects CARs in chronic lymphocytic leukemia -- ready to drive Progress and prospects for engineered T cell therapies Genetically modified T cells for the treatment of malignant disease Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection Clinical application of adoptive T cell therapy in solid tumors Chimeric antigen receptor therapy for cancer Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities Toxicity and management in CAR T-cell therapy T cell engineering as therapy for cancer and HIV: our synthetic future Therapeutic genome editing: prospects and challenges Engineered T cells for cancer treatment Strategies to genetically engineer T cells for cancer immunotherapy.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.CAR-modified T-cell therapy for cancer: an updated review.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Immunotherapy for metastatic solid cancers Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Clinical application of genetically modified T cells in cancer therapy.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Treating cancer with genetically engineered T cells.T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene

P2860

Q21131200-792C06E1-5DA5-4DFE-9CBC-E16A2566FBAC Q24632975-5CB7697B-3075-464A-8EA5-2183735713A0 Q26753082-A92C7949-7147-4A25-9D79-596D819CC468 Q26830526-A5CF19EB-E107-406E-B493-22CFDAD75D3B Q26852923-6A776002-379F-4D92-82A7-0C51F0C9318B Q26860657-4989C7E1-AA6D-4166-81E7-2FC5B21C3300 Q27005830-6F02B919-26BE-4A5B-93D6-D6743CD2ADF8 Q27011283-E0F25D0B-2949-43E0-81EC-F5CB891EFB18 Q27013599-0EF8EDB3-6936-4408-B93D-B99E652DFAA5 Q27027876-669B4DCE-9BBC-41A0-9A1D-AD88BF3EA990 Q27312288-E46A4356-C198-47FB-BED4-E3870857A80B Q28074619-A879BE71-066A-427F-A8E7-80C283B4F75E Q28075314-7E494C9C-FD2A-4CE6-9EF6-8F89FE58A71C Q28082253-AD0D182D-A439-4F53-A1FF-6DD4FFD3EBD5 Q28087380-4952A5C7-9CC5-4A98-82BB-6DF74DB80ECD Q33578792-6460CF9F-A35A-4FC0-B115-983152830358 Q33655849-EAE534C6-63DB-4073-9843-BF4D67280C46 Q33993529-22077D0B-B133-40E5-BF39-8CDFD528D7E9 Q34030602-96A1BFE8-AF53-4328-BFCC-7E94E142F7D7 Q34044213-DC4AB469-86F5-47E8-AE02-F8F5BE4C832A Q34073529-A45D53DE-0B0E-45F8-9B06-708565BAD12E Q34219970-54619953-815C-4487-A6D5-470687A00CF6 Q34248531-8DE3BC8E-3AD5-4B6A-97C9-76F01EA13194 Q34270375-C60FC220-7F9F-4B78-B5A9-C5176D3D94EC Q34309388-4A2C50CD-4221-41A1-A5B3-1B7943B99583 Q34511646-8879AC44-BCD1-4B9F-AED9-2673292B219F Q34520155-3AEDD7B2-4B9A-48D5-9BE2-FD5B79FA443A Q34592273-89CBBEC9-8E3F-4EE9-AF22-34B1D15E1BC4 Q34729692-744E80AD-7713-41A6-803F-4C7F618C3350 Q35353365-7AAF1F2E-DA0A-4AEC-A2A6-78EDFBF378CB Q35483599-950D9E02-F95C-44F6-A0E9-EE044F1A2828 Q35598804-0B1B09C0-AB64-4B31-84B7-BF3181117B0A Q35604043-B6D3D2DC-0B54-4297-8CD6-AE5D0C2A2674 Q35661999-053118E4-733E-4ED0-82E8-6C858000FD1C Q35745453-B94D2DE8-6B9C-4DD1-B018-F5AD35FA896C Q35802193-4034E00F-ADF2-4D77-B276-97E88D30AB3E Q35917978-95907CAC-698D-4CB0-AD1F-83E7AF469701 Q35953372-016B4A79-7D8C-44AE-A4E4-62D9208FA653 Q35986612-E7E22C2C-64DD-40F8-98B1-A0F3F452E612 Q36242630-2DF1DE72-3A5B-4586-913D-9207AF9FB3C7

P2860

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

http://www.wikidata.org/entity/Q33708774

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immune responses to transgene ...... th ex vivo-engineered T cells.

@ast

Immune responses to transgene ...... th ex vivo-engineered T cells.

@en

type

label

Immune responses to transgene ...... th ex vivo-engineered T cells.

@ast

Immune responses to transgene ...... th ex vivo-engineered T cells.

@en

prefLabel

Immune responses to transgene ...... th ex vivo-engineered T cells.

@ast

Immune responses to transgene ...... th ex vivo-engineered T cells.

@en

P1433

Q33708774-F891B0AD-3411-45C1-9ED0-BD2E3F9B1723

P1476

Q33708774-C59BD064-A4DC-42B8-B460-BF9BD0AD70D0

P2093

Q33708774-3889180F-C77D-4754-89B9-40BEBACA17A4

Q33708774-3AB2ED27-4D13-4D2C-9B4B-D0CB312D5FE9

Q33708774-469065AF-FAE6-458A-BE82-87079E461DFB

Q33708774-7625F308-FB5B-4F46-A75E-13ADD4694016

Q33708774-8C3ADC50-C695-4D10-B6E6-5BCA401D0E5C

Q33708774-8D26CC16-AEAF-463C-8320-07B2867F60F6

Q33708774-BAAAF83B-F59D-45A4-BA87-269F170F43B3

Q33708774-C147945B-F3F8-49CC-9E5A-032F336FCA52

Q33708774-D357277B-F93F-452E-A268-DEF221B5C8E8

Q33708774-E9113DCF-E68F-4544-8E77-3807F1B0E5F3

P304

Q33708774-2B48FAF0-503D-42B0-8D37-B79B0B0EEBCC

P31

Q33708774-64DC73B1-D255-4A5B-BCF9-65D0B2BDD1A4

P356

Q33708774-73D6FC45-7093-4BBB-B6AA-92CE85B6BB78

P407

Q33708774-E6479EA6-9D92-4F06-9381-37FD019422BF

P433

Q33708774-37E38E2E-AE5D-4DC3-BE75-92B4F9FCED1F

P478

Q33708774-85BC01AD-4D95-4C42-A913-E9EE9F88DD81

P577

Q33708774-6F78B955-5B99-4066-9088-898856C0AEDB

P5875

Q33708774-91F90CB1-DD13-4158-97F3-62C41B70A53A

P698

Q33708774-9CD28E84-23A9-4AA2-A8E1-BCC64623EA15

P356

BLOOD-2010-07-294520

P1433

P1476

Immune responses to transgene ...... th ex vivo-engineered T cells.

@en

P2093

Cor H J Lamers

http://www.w3.org/2001/XMLSchema#string

Egbert Oosterwijk

http://www.w3.org/2001/XMLSchema#string

Jan W Gratama

http://www.w3.org/2001/XMLSchema#string

Jeannette Oosterwijk-Wakka

http://www.w3.org/2001/XMLSchema#string

Marieke Broertjes

http://www.w3.org/2001/XMLSchema#string

Pascal van Elzakker

http://www.w3.org/2001/XMLSchema#string

Ralph Willemsen

http://www.w3.org/2001/XMLSchema#string

Reno Debets

http://www.w3.org/2001/XMLSchema#string

Sabine van Steenbergen-Langeveld

http://www.w3.org/2001/XMLSchema#string

Stefan Sleijfer

http://www.w3.org/2001/XMLSchema#string

P304

72-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-07-294520

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47300443

http://www.w3.org/2001/XMLSchema#string

P698

20889925

http://www.w3.org/2001/XMLSchema#string